Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

SSBP2 variants are associated with survival in glioblastoma patients.

Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Wiemels JL, Tihan T, Prados MD, Chang SM, Berger MS, Kosel ML, Fridley BL, Lachance DH, O'Neill BP, Buckner JC, Thompson RC, Nabors LB, Olson JJ, Brem S, Madden MH, Browning JE, Wiencke JK, Egan KM, Jenkins RB, Wrensch MR.

Clin Cancer Res. 2012 Jun 1;18(11):3154-62. doi: 10.1158/1078-0432.CCR-11-2778. Epub 2012 Apr 3.

2.

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.

Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D.

Ann Oncol. 2009 Jan;20(1):175-81. doi: 10.1093/annonc/mdn548. Epub 2008 Aug 7.

PMID:
18687982
3.

The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.

McDonald KL, Rapkins RW, Olivier J, Zhao L, Nozue K, Lu D, Tiwari S, Kuroiwa-Trzmielina J, Brewer J, Wheeler HR, Hitchins MP.

Eur J Cancer. 2013 Jan;49(2):360-8. doi: 10.1016/j.ejca.2012.08.012. Epub 2012 Sep 10.

PMID:
22975219
4.

Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma.

Scheurer ME, Amirian E, Cao Y, Gilbert MR, Aldape KD, Kornguth DG, El-Zein R, Bondy ML.

Clin Cancer Res. 2008 Oct 15;14(20):6640-6. doi: 10.1158/1078-0432.CCR-07-4681.

5.

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL.

Neuro Oncol. 2015 Dec;17(12):1589-98. doi: 10.1093/neuonc/nov064. Epub 2015 Apr 24.

6.

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.

JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

7.
8.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

9.

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.

Kristensen LS, Michaelsen SR, Dyrbye H, Aslan D, Grunnet K, Christensen IJ, Poulsen HS, Grønbæk K, Broholm H.

J Neuropathol Exp Neurol. 2016 Mar;75(3):246-55. doi: 10.1093/jnen/nlv024. Epub 2016 Feb 16.

10.

Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.

Jacobs DI, Liu Y, Gabrusiewicz K, Tsavachidis S, Armstrong GN, Zhou R, Wei J, Ivan C, Calin G, Molinaro AM, Rice T, Bracci PM, Hansen HM, Wiencke JK, Wrensch MR, Heimberger AB, Bondy ML.

J Neurooncol. 2018 Jan;136(1):33-39. doi: 10.1007/s11060-017-2622-6. Epub 2017 Sep 30.

11.

The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.

Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW.

J Neurooncol. 2013 Apr;112(2):277-83. doi: 10.1007/s11060-013-1060-3. Epub 2013 Feb 2.

PMID:
23377829
12.

Genetic variations in EGF and EGFR and glioblastoma outcome.

Sjöström S, Andersson U, Liu Y, Brännström T, Broholm H, Johansen C, Collatz-Laier H, Henriksson R, Bondy M, Melin B.

Neuro Oncol. 2010 Aug;12(8):815-21. doi: 10.1093/neuonc/noq018. Epub 2010 Mar 2.

13.

Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.

Foro Arnalot P, Pera O, Rodriguez N, Sanz X, Reig A, Membrive I, Ortiz A, Granados R, Algara M.

Clin Transl Oncol. 2017 Oct;19(10):1225-1231. doi: 10.1007/s12094-017-1659-5. Epub 2017 Apr 7.

PMID:
28389881
14.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
15.

MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.

Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):661-7. doi: 10.1016/j.ijrobp.2011.12.086. Epub 2012 Mar 11.

PMID:
22414280
16.

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

Wang X, Chen JX, Liu JP, You C, Liu YH, Mao Q.

Ann Surg Oncol. 2014 Apr;21(4):1337-44. doi: 10.1245/s10434-013-3380-0. Epub 2013 Nov 19.

PMID:
24248532
17.

Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).

Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.

J Neurooncol. 2015 Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30.

PMID:
26423801
18.

Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.

Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

19.

A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma.

Pei C, Chen H, Jia X, Yan L, Zou Y, Jiang C, Jin H, Kang C, Jiang T, Ren H.

Int J Neurosci. 2013 Feb;123(2):114-20. doi: 10.3109/00207454.2012.738735. Epub 2012 Nov 19.

PMID:
23057844
20.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389

Supplemental Content

Support Center